We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Esperion Therapeutics Inc | NASDAQ:ESPR | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.055 | 2.28% | 2.465 | 2.46 | 2.47 | 2.63 | 2.44 | 2.44 | 3,704,659 | 15:56:49 |
From Nov 2023 to May 2024
By Denny Jacob
Esperion Therapeutics received Food and Drug Administration approval for updates to nexletol and nexlizet.
The pharmaceutical company said the FDA approved an updated LDL-cholesterol lowering indication for nexletol and nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.
Esperion said other changes include the maximally tolerated qualifier for statin use has been removed, as well as the removal of the prior limitation of use stating the effect of the two treatments on cardiovascular morbidity and mortality has not been determined.
The Ann Arbor, Mich.-based company said the labeling modifications don't impact the full pending label approvals for cardiovascular risk reduction indications for nexletol and nexlizet, which it said remains on track for anticipated approval in the first quarter.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 13, 2023 16:31 ET (21:31 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Esperion Therapeutics Chart |
1 Month Esperion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
